Compare BHST & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | NSRX |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 38.9M |
| IPO Year | 2017 | 2024 |
| Metric | BHST | NSRX |
|---|---|---|
| Price | $1.49 | $3.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $10.50 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 31.0K | 14.8K |
| Earning Date | 11-12-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.59 | N/A |
| Revenue Next Year | $29.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.98 |
| 52 Week High | $12.80 | $9.50 |
| Indicator | BHST | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.91 | 59.59 |
| Support Level | N/A | $2.97 |
| Resistance Level | $1.77 | $4.49 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 15.73 | 81.70 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.